HK1047893A1 - Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran - Google Patents

Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran

Info

Publication number
HK1047893A1
HK1047893A1 HK03100127A HK03100127A HK1047893A1 HK 1047893 A1 HK1047893 A1 HK 1047893A1 HK 03100127 A HK03100127 A HK 03100127A HK 03100127 A HK03100127 A HK 03100127A HK 1047893 A1 HK1047893 A1 HK 1047893A1
Authority
HK
Hong Kong
Prior art keywords
melagatran
receptor antagonist
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
HK03100127A
Other languages
English (en)
Inventor
John Dixon
Robert Humpries
Gavin Jarvis
Ian Kirk
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1047893A1 publication Critical patent/HK1047893A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100127A 1999-12-01 2003-01-06 Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran HK1047893A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
PCT/SE2000/002378 WO2001039781A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
HK1047893A1 true HK1047893A1 (en) 2003-03-14

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100127A HK1047893A1 (en) 1999-12-01 2003-01-06 Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran

Country Status (33)

Country Link
US (2) US20030032618A1 (xx)
EP (2) EP1719526A3 (xx)
JP (1) JP2003515565A (xx)
KR (1) KR100785953B1 (xx)
CN (1) CN1402639A (xx)
AR (1) AR033658A1 (xx)
AT (1) ATE332698T1 (xx)
AU (1) AU781691B2 (xx)
BR (1) BR0016043A (xx)
CA (1) CA2391161C (xx)
CO (1) CO5271717A1 (xx)
CY (1) CY1105211T1 (xx)
CZ (1) CZ300925B6 (xx)
DE (1) DE60029340T2 (xx)
DK (1) DK1237559T3 (xx)
EE (1) EE05127B1 (xx)
ES (1) ES2267591T3 (xx)
HK (1) HK1047893A1 (xx)
HU (1) HU230890B1 (xx)
IL (1) IL149495A0 (xx)
IS (1) IS2841B (xx)
MX (1) MXPA02004871A (xx)
MY (1) MY128896A (xx)
NO (1) NO331215B1 (xx)
NZ (2) NZ530058A (xx)
PT (1) PT1237559E (xx)
RU (1) RU2242232C2 (xx)
SE (1) SE9904377D0 (xx)
SI (1) SI1237559T1 (xx)
SK (1) SK288707B6 (xx)
TW (1) TWI251491B (xx)
WO (1) WO2001039781A1 (xx)
ZA (1) ZA200203707B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
CN101253179B (zh) * 2005-09-21 2010-12-29 株式会社钟根堂 S-氯吡格雷的树脂酸盐复合物及其制备方法
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PT2498731T (pt) 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
PL2964233T3 (pl) 2013-03-09 2022-04-25 Chiesi Farmaceutici S.P.A. Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych
KR20200018481A (ko) 2017-06-23 2020-02-19 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
CA2107667A1 (en) * 1991-04-06 1992-10-07 Anthony Howard Ingall Atp analogues
PL175623B1 (pl) * 1993-02-10 1999-01-29 Astra Pharma Prod N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
PL182680B1 (pl) * 1995-07-11 2002-02-28 Astrazeneca Ab Nowe inhibitory skupiania się płytek krwi
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
WO2005007191A1 (ja) * 2003-07-16 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物

Also Published As

Publication number Publication date
AU1910901A (en) 2001-06-12
PT1237559E (pt) 2006-10-31
ES2267591T3 (es) 2007-03-16
SK7502002A3 (en) 2003-02-04
CZ300925B6 (cs) 2009-09-09
RU2002117296A (ru) 2004-01-20
EP1719526A2 (en) 2006-11-08
IS2841B (is) 2013-08-15
IS6398A (is) 2002-05-27
US20060270607A1 (en) 2006-11-30
CN1402639A (zh) 2003-03-12
BR0016043A (pt) 2002-07-23
CO5271717A1 (es) 2003-04-30
EE05127B1 (et) 2009-02-16
EP1719526A3 (en) 2007-04-25
NZ530058A (en) 2005-04-29
CZ20021887A3 (cs) 2002-11-13
NO20022606D0 (no) 2002-05-31
IL149495A0 (en) 2004-03-28
AU781691B2 (en) 2005-06-09
SE9904377D0 (sv) 1999-12-01
KR100785953B1 (ko) 2007-12-14
MXPA02004871A (es) 2002-08-30
TWI251491B (en) 2006-03-21
WO2001039781A1 (en) 2001-06-07
DK1237559T3 (da) 2006-10-30
EP1237559B1 (en) 2006-07-12
PL355841A1 (en) 2004-05-17
RU2242232C2 (ru) 2004-12-20
MY128896A (en) 2007-02-28
NO20022606L (no) 2002-07-11
HU230890B1 (hu) 2018-12-28
NZ518904A (en) 2004-02-27
HUP0203585A3 (en) 2005-01-28
EE200200271A (et) 2003-06-16
US20030032618A1 (en) 2003-02-13
NO331215B1 (no) 2011-11-07
ZA200203707B (en) 2003-10-29
ATE332698T1 (de) 2006-08-15
AR033658A1 (es) 2004-01-07
HUP0203585A2 (hu) 2003-03-28
DE60029340T2 (de) 2007-07-19
JP2003515565A (ja) 2003-05-07
CY1105211T1 (el) 2010-03-03
SK288707B6 (sk) 2019-10-02
SI1237559T1 (sl) 2007-02-28
CA2391161C (en) 2010-10-05
KR20020069201A (ko) 2002-08-29
DE60029340D1 (de) 2006-08-24
CA2391161A1 (en) 2001-06-07
EP1237559A1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
HK1047893A1 (en) Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran
IL142958A0 (en) Vitronectin receptor antagonist pharmaceuticals
EP1229910A4 (en) integrin
IL146632A0 (en) Pharmaceutical tablets
EP1194151A4 (en) ANTAGONISTS OF THE INTEGRIN RECEPTORS
HUP0201524A2 (en) Bradykinin receptor antagonists
AU2001271435A1 (en) Vitronectin receptor antagonist pharmaceuticals
AU2371400A (en) Vitronectin receptor antagonist pharmaceuticals
IL146151A0 (en) Human-g-protein receptor
HK1046140A1 (zh) 固體藥劑
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
AU141186S (en) Tablet
IL147507A0 (en) T-cell receptor y and uses thereof
IL146146A0 (en) Integrin receptor antagonists
EP1223946A4 (en) HUMAN NEUROPEPTIDE RECEPTOR
GB9909154D0 (en) Pharmaceutical formulation
GB9926251D0 (en) Pharmaceutical formulation
GB9900166D0 (en) Pharmaceutical device
CA88762S (en) Pharmaceutical tablet
SI1187592T1 (sl) Antagonisti alfa V integrinskega receptorja
SI1140203T1 (sl) Viktronektin receptor farmacevtski antagonist
GB9926437D0 (en) Pharmaceutical
GB9926434D0 (en) Pharmaceutical
HU9902398D0 (en) Pharmaceutical preparation
HUP0201540A3 (en) Serotomin and 5ht1a receptor antagonist phenoxypropylamine derivatives and use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101129